Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing

Ernexa reported that ERNA-201 showed encouraging disease-modifying activity in the collagen-induced arthritis model, an industry-standard preclinical test. The result provides proof-of-concept for the company’s engineered synthetic iMSC platform in inflammatory disease applications beyond oncology, though no quantitative efficacy data or clinical-stage results were disclosed.